Evidence map›Paper›PMID 36564488›Full record

SynthesisMolecular psychiatry2023

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression.

Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Nakao Iwata

Full text readMeta-AnalysisLetter
In one paragraph

Synthesis in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Taro KishiDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan. tarok@fujita-hu.ac.jp.ORCID 0000-0002-9237-2236
Kenji SakumaDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Masakazu HatanoDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Makoto OkuyaDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Yuki MatsudaDepartment of Psychiatry, Jikei University School of Medicine, Minato-ku, Tokyo, 105-8461, Japan.
Masaki KatoDepartment of Neuropsychiatry, Kansai Medical University, Hirakata, Osaka, 573-1191, Japan.ORCID 0000-0001-6727-7272
Nakao IwataDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.ORCID 0000-0003-3189-6076

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Major Depressive DisorderAntidepressive AgentsHumansRecurrenceAntidepressive Agents

Identifiers

PMID36564488
PMCPMC10005929

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read12
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.